Burden and Risk Factors of Gout, Low Back Pain, Osteoarthritis, and Rheumatoid Arthritis - China, 1990-2023

Kun Xu1, Feng Pan1, Kunzhi Zhu1

  • 1Joint Surgery, Beijing Jishuitan Hospital Guizhou Hospital, Guiyang City, Guizhou Province, China.

China CDC Weekly
|January 16, 2026
PubMed

Insights

Musculoskeletal disease burdens from gout, osteoarthritis, and rheumatoid arthritis are rising, while low back pain is declining. These trends, particularly impacting adults aged 40-80, require targeted public health interventions.

Area of Science:

  • Public Health
  • Epidemiology
  • Gerontology

Background:

  • Musculoskeletal disorders (MSDs) like gout, low back pain (LBP), osteoarthritis (OA), and rheumatoid arthritis (RA) present a significant global health challenge, exacerbated by aging populations.
  • China faces unique demographic shifts and occupational changes, necessitating updated data for effective prevention strategies.

Purpose of the Study:

  • To analyze the trends and projections of MSD burdens in China from 1990 to 2043 using Global Burden of Disease (GBD) 2023 data.
  • To identify age- and gender-specific variations in MSD prevalence and impact.

Main Methods:

  • Utilized Global Burden of Disease (GBD) 2023 data spanning from 1990 to 2023.
  • Employed predictive modeling to forecast disease trajectories up to 2043.
  • Analyzed demographic variations, focusing on age and gender differences.

Main Results:

  • The disease burdens of gout, OA, and RA showed continuous increases from 1990-2023, while LBP burden decreased.
  • Projected trends indicate a persistent rise in gout, OA, and RA burdens and a decline in LBP through 2043.
  • Significant age- and gender-specific disparities were observed, with the 40-80 age group most affected.

Conclusions:

  • The increasing burden of gout, OA, and RA, especially in the 40-80 age group, demands immediate public health action aligned with "Healthy China 2030" goals.
  • Interventions should focus on modifiable risk factors (e.g., BMI, ergonomics), targeted screening for high-risk groups (males for gout; females for OA/RA), and improved healthcare systems.
  • Proactive management and prevention strategies are crucial to mitigate long-term disability from these prevalent MSDs.
Abstract